TVGN net incomeQ2 2026-$5.76M
TVGN net income was -$5.76M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.50M a year earlier. For the full fiscal 2025 it was -$26.28M, compared with -$13.73M in fiscal 2024.
Tevogen Inc. (TVGN) financials
For the twelve months ended Jun 30, 2026, Tevogen Inc. reported -$21.61M of net income.
- Net income, TTM
- -$21.61M
- Cash
- $1.08M
- Market cap
- $407.3M
FY2022FY2025
FY2023FY2025
TVGN revenue and earnings growth
TVGN EPSQ2 2026-$1.52
TVGN diluted EPS was -$1.52 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.71 a year earlier. For the full fiscal 2025 it was -$8.08, compared with -$3.50 in fiscal 2024.
TVGN free cash flowFY2025-$12.39M
TVGN free cash flow was -$12.39M for fiscal 2025 (ended Dec 31, 2025).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $11.11M | $31.03M | $4.40M | - |
| Selling, general and admin | $15.03M | $22.53M | $4.44M | $953.1K |
| Operating income | -$26.14M | -$53.56M | -$8.84M | - |
| Interest expense | - | $184.0K | $1.21M | - |
| Income tax | $4.8K | $1.8K | - | - |
| Net income | -$26.28M | -$13.73M | -$60.48M | $4.41M |
| EPS, basic | -$8.08 | -$3.50 | -$2.44 | - |
| EPS, diluted | -$8.08 | -$3.50 | -$2.44 | - |
| Diluted shares | 3.3M | 2.9M | 24.8M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $552.4K | $1.28M | $1.05M | $5.48M |
| Current assets | $1.54M | $2.36M | $1.72M | $274.4K |
| Total assets | $4.38M | $3.46M | $5.51M | $357.14M |
| Current liabilities | $7.07M | $9.04M | $85.48M | $350.5K |
| Short-term debt | - | - | - | $0 |
| Long-term debt | - | - | $14.22M | - |
| Total debt | - | - | $14.22M | - |
| Total liabilities | $12.62M | $10.14M | $99.93M | $15.06M |
| Shareholders' equity | -$8.23M | -$6.67M | -$94.43M | -$33.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$12.33M | -$12.00M | -$8.17M | -$215.4K |
| Capital expenditures | $64.4K | - | $133.0K | - |
| Free cash flow | -$12.39M | - | -$8.30M | - |
| Investing cash flow | -$64.4K | - | -$133.0K | - |
| Financing cash flow | $11.66M | $12.23M | $3.87M | - |
| Share repurchases | - | - | $342.98M | - |
| Stock-based compensation | $16.22M | $40.76M | - | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.28M | $3.13M | $2.11M | $3.11M | $2.70M | $3.20M | $2.84M | $3.26M | $4.12M | $20.81M | $908.0K | $1.12M |
| Selling, general and admin | $2.38M | $2.27M | $2.50M | $2.62M | $2.74M | $7.16M | $6.53M | $2.82M | $4.47M | $8.71M | $1.10M | $1.21M |
| Operating income | -$5.66M | -$5.40M | -$4.61M | -$5.73M | -$5.44M | -$10.36M | -$9.36M | -$6.09M | -$8.60M | -$29.52M | -$2.01M | -$2.33M |
| Interest expense | - | - | - | - | - | $24.6K | $15.8K | $12.5K | -$6 | $155.8K | $317.5K | $299.9K |
| Net income | -$5.76M | -$5.45M | -$4.68M | -$5.73M | -$5.50M | -$10.37M | -$9.44M | -$5.88M | -$9.66M | $11.26M | -$3.63M | -$3.90M |
| EPS, basic | -$1.52 | -$1.61 | - | -$0.03 | -$1.71 | -$3.25 | - | -$0.03 | -$0.04 | $0.08 | - | -$0.03 |
| EPS, diluted | -$1.52 | -$1.61 | - | -$0.03 | -$1.71 | -$3.25 | - | -$0.03 | -$0.04 | -$0.26 | - | -$0.03 |
| Diluted shares | 3.8M | 3.5M | - | 196.0M | 3.3M | 3.2M | - | 170.2M | 154.2M | 142.4M | - | 120.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.08M | $692.3K | $552.4K | $1.04M | $685.2K | $1.97M | $1.28M | $2.33M | $1.14M | $1.32M | $1.05M | $2.61M |
| Current assets | $2.01M | $2.14M | $1.54M | $2.12M | $2.06M | $3.08M | $2.36M | $3.53M | $2.45M | $2.40M | $1.72M | $399.5K |
| Total assets | $4.73M | $4.92M | $4.38M | $4.49M | $4.27M | $4.07M | $3.46M | $4.29M | $3.31M | $3.36M | $5.51M | $26.41M |
| Current liabilities | $6.15M | $7.27M | $7.07M | $6.74M | $8.08M | $8.72M | $9.04M | $10.42M | $10.61M | $8.94M | $85.48M | $1.83M |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | $14.22M | - |
| Total debt | - | - | - | - | - | - | - | - | - | - | $14.22M | - |
| Total liabilities | $13.62M | $14.76M | $12.62M | $12.32M | $13.75M | $11.79M | $10.14M | $10.48M | $10.94M | $9.17M | $99.93M | $16.56M |
| Shareholders' equity | -$8.89M | -$9.84M | -$8.23M | -$7.82M | -$9.48M | -$7.72M | -$6.67M | -$6.19M | -$7.66M | -$5.80M | -$94.43M | -$90.80M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.01M | -$2.73M | -$2.18M | -$3.65M | -$3.19M | -$3.31M | -$3.05M | -$3.80M | -$2.98M | -$2.16M | -$1.98M | -$1.80M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$1.98M | -$1.80M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Financing cash flow | $3.40M | $2.87M | $1.76M | $4.00M | $1.90M | $4.00M | $2.00M | $5.00M | $2.80M | $2.43M | $422.3K | $950.0K |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $9.71M | $0 |
| Stock-based compensation | $3.29M | $2.85M | $2.45M | $3.24M | $3.24M | $7.29M | $6.96M | $3.33M | $4.14M | $26.33M | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.33 | 0.29 | 0.22 | 0.31 | 0.25 | 0.35 | 0.26 | 0.34 | 0.23 | 0.27 | 0.02 | 0.22 |
Source: XBRL data Tevogen Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TVGN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TVGN | - | - | -$21.61M | - | $407.3M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.89B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $208.48B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $90.38B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.58B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.46B |
| RVMD | $0 | - | -$1.13B | - | $37.27B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.50B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $16.94B |
TVGN FAQ
4 questionsIs TVGN profitable?
No. Tevogen Inc. reported a net loss of $21.61M for the twelve months ended Jun 30, 2026.How much cash and debt does TVGN have?
Tevogen Inc. reported $1.08M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did TVGN last report financial results?
The latest statements here come from Tevogen Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this TVGN financial data come from?
Quantisnow builds these statements from the structured XBRL data Tevogen Inc. files with the SEC. It is provided for information only and is not investment advice.